Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab
Campani C, Bamba-Funck J, Campion B, Sidali S, Blaise L, Ganne-Carrié N, Demory A, Sutter O, Larrey E, Evain M, Ghannouchi H, Wagner M, Marra F, Sutton A, Allaire M, Nault JC. Liver Int. 2023 Mar;43(3):708-717. doi: 10.1111/liv.15487. Epub 2022 Dec 14. Background: The combination of atezolizumab and bevacizumab (AtezoBev) is the current first-line treatment …